Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New breast cancer targets to be evaluated by Domainex

This article was originally published in Scrip

Executive Summary

Tankyrase and IKK-epsilon, two new potential drug targets in breast cancer, are to be the subject of a research collaboration between the UK drug discovery company Domainex and the Institute of Cancer Research's Breakthrough Breast Cancer Research Centre. Domainex will apply its virtual hit-finding process, LeadBuilder, to the targets, and the collaborators will then partner with larger organisations to develop them further. The Breast Cancer Research Centre is led by Professor Alan Ashworth and has 120 researchers focused on the study of the disease.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC001147

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel